NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies
PharmaTalkRadio6 Mars 2020

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include: Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combination with PD-1 checkpoint inhibitionClinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancerCombinations under investigation To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(461)

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
medicinvetarna
rss-ufobortom-rimligt-tvivel
svd-nyhetsartiklar
rss-spraket
det-morka-psyket
rss-vetenskapsradion
sexet
halsorevolutionen
paranormalt-med-caroline-giertz
dumforklarat
rss-vetenskapsradion-2
rss-arkeologi-historia-podden-som-graver-i-vart-kulturlandskap
vetenskapsradion
rss-ronden
4health-med-anna-sparre
rss-italiensk-dagbok